CEACAM5 and breast cancer: Consistently, Zhao et al. (2014), reported that miR-195 achieved a higher sensitivity (69%) and specificity (89.2%) for the diagnosis of BC patients, in comparison to the carcinoembryonic antigen (CEA, sensitivity: 15.08%) and carbohydrate antigen 15–3 (CA15-3, sensitivity: 21.1%).